Last reviewed · How we verify
NCT06227689
Effectiveness of Vaccine Chatbot on HPV Vaccine Awareness and Vaccination in China
NA trial testing Vaccine chatbot that offering HPV vaccine-related information in HPV Vaccine in 1,800 participants. Currently enrolling.
30 June 2024
Quick facts
| Lead sponsor | Fudan University |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | health services research |
| Enrollment | 1,800 |
| Start date | 18 January 2024 |
| Primary completion | 30 June 2024 |
| Estimated completion | 31 July 2024 |
| Sites | 2 locations across China |
Drugs / interventions tested
- Vaccine chatbot that offering HPV vaccine-related information
Conditions studied
- HPV Vaccine — all drugs for HPV Vaccine →
Sponsor
Fudan University
Who can join
Adults 10 to 16, female only, with HPV Vaccine. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This interventional study targets female students in junior middle school. It goal is to evaluate the effectiveness of a vaccine chatbot on HPV vaccine awareness and vaccination. The main questions it aims to answer are: 1. How will the novel digital tool, a vaccine chatbot, impact eligible parents' awareness and knowledge of HPV vaccines, their willingness to vaccinate their daughters, and vaccination status of female students. 2. How is the vaccine chatbots accepted by all stakeholders, and what are the facilitators of and barriers to implementing vaccine chatbot promotion campaign. The intervention group will go through the intervention measure while the control group will not: 1. The intervention group will be invited to use the HPV vaccine chatbot online through WeChat , the mostly widely used social media platform in mainland China, or any web browsers. They can ask any questions related to the HPV vaccine and get validated answers from the chatbot immediately. The intervention lasts two weeks, with invitations sent every four days to reinforce the intervention. 2. The control group will not use the chatbot during the intervention duration. Researchers will compare participants' HPV vaccine awareness, and vaccination intention and status after intervention between intervention group and control group to evaluate if the vaccine chatbot improves HPV vaccine awareness and vaccination.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
A vaccine chatbot intervention for parents to improve HPV vaccination uptake among middle school girls: a cluster randomized trial.
Hou Z, Wu Z, Qu Z, Gong L, et al · · 2025 · cited 10× · PMID 40195450 · DOI 10.1038/s41591-025-03618-6
Verify or expand the search:
- PubMed search for NCT06227689
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for HPV Vaccine
Currently open trials in the same condition.
- NCT06831929 — HPV Ends Here: Increasing Uptake of the HPV Vaccine · NA · recruiting
- NCT05291871 — Immunogenicity of Fractional Dose of the HPV Vaccines · Phase 4 · active not recruiting
- NCT04235257 — Intradermal, Fractional Dose of HPV Vaccines: · Phase 4 · active not recruiting
Other Fudan University trials
Trials by the same sponsor.
- NCT06196671 — Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer · Phase 2 · not yet recruiting
- NCT07423611 — ctDNA-Guided Chemotherapy Omission With Ribociclib Plus Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer · Phase 2 · not yet recruiting
- NCT07410559 — Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Bre · Phase 2 · not yet recruiting
- NCT07490119 — Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal Cancer · Phase 2 · not yet recruiting
- NCT07497919 — A Study of Becotatug Vedotin Combined With Pucotenlimab in the Treatment of EGFR-Positive Advanced Penile Cancer · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06227689 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fudan University
- Last refreshed: 12 June 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06227689.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing